ArticleAnnals of medicine2025
Unmasking the 'rods and rings' antinuclear antibody pattern: a sign of hepatitis C treatment and a risk factor for cerebrovascular disease.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe rods and rings (RR) antinuclear antibody (ANA) pattern (AC-23) is predominantly associated with hepatitis C virus (HCV) treatment, particularly involving ribavirin (RBV). Its relevance in other clinical conditions is unclear. This study aims to explore the RR ANA pattern's associations with clinical conditions, including potential links to cerebrovascular disease (CVD).
objectivesTo investigate the clinical characteristics of patients displaying the RR ANA pattern, assess its associations with autoimmune diseases and other conditions and evaluate the potential risk of CVD in patients with high ANA titres. MATERIALS AND
methodsThis retrospective study analyzed 43,633 ANA samples collected at Chang Gung Memorial Hospital, Taiwan (August 2019-June 2021). ANA titres ≥1:160 were positive; the RR ANA pattern was identified using the EUROPattern system. Data were obtained from medical records. Statistical analyses (Mann-Whitney U, chi-squared, Fisher's exact tests) were conducted, with
resultsAmong 43,633 samples, 9,999 (22.9%) were ANA-positive, with 55 samples (0.56%) from 35 patients showing the RR ANA pattern. Most (88.6%) RR-positive patients had HCV infection, with 92.3% receiving RBV treatment. Liver comorbidities (cirrhosis 38.7%, fatty liver 51.6%, hepatocellular carcinoma 25.8%) were prevalent. Among four HCV-negative patients, three were on beta-blockers. Patients with high ANA titres (≥1:640) showed a significantly higher prevalence of CVD than those with low titres (≤1:320, DISCUSSION AND
conclusionsThis study confirms a strong association between the RR ANA pattern and HCV treatment, while suggesting a potential link to CVD at high ANA titres. RR positivity in HCV-negative patients also suggests other triggers, including beta-blockers. These findings underscore the need for further research into the broader clinical implications of the RR ANA pattern and its association with inflammatory diseases.KEY MESSAGEThe anti-rods and rings (anti-RR) ANA pattern, once considered specific to HCV therapy, can also appear in non-HCV patients.High-titre anti-RR positivity may be associated with an increased risk of cerebrovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.